Mass General Hospital

Harvard Medical School

Welcome to the MGH Center for Women’s Mental Health

Welcome

Welcome to The Ammon-Pinizzotto Center for Women’s Mental Health at MGH. Our Center, established in 1989, has been renamed following the generous gift from Carol Ammon and Dr. Marie Pinizzotto. These resources will be used to realize the overarching mission of the Center.

This website provides a range of current information including discussion of new research findings in women’s mental health and how such investigations inform day-to-day clinical practice. Despite the growing number of studies being conducted in women’s health, the clinical implications of such work are frequently controversial, leaving patients with questions regarding the most appropriate path to follow. Providing these resources to patients and their doctors so that individual clinical decisions can be made in a thoughtful and collaborative fashion dovetails with the mission of our Center.

The National Pregnancy Registry for Psychiatric Medications:

All pregnant women ages 18-45 are eligible to enroll in the registry. The primary goal of this Registry is to determine the frequency of major malformations, such as heart defects, cleft lip, or neural tube defects, in infants exposed to atypical antipsychotics and antidepressants during pregnancy.  We are currently seeking both controls and those being treated with atypical antipsychotics and/ or antidepressants. For more information, please visit this page, call 1-866-961-2388 or e-mail registry@womensmentalhealth.org.

 

 EnBrace HR for MDD Relapse Prevention in         Women Trying to Conceive and Early Pregnancy:

 

Are you pregnant or planning a pregnancy? Do you feel depressed or have a history of depression? If you are less than 28 weeks pregnant or trying to conceive and have experienced depression now or in the past, you may be eligible to take part in a research study for the treatment of depression with a prenatal supplement. For more information, please visit this page, call Gina at 617-643-9284 or e-mail gsavella@partners.org.

 

 

Lifestyle Intervention Research Study Opportunity:

Are you pregnant or planning to become pregnant? Do you have a history of depression? Do you want to lose weight or have a healthier lifestyle? You may be eligible to participate in a research study evaluating a new lifestyle intervention for weight loss. Participants will receive 10 sessions of therapy at no cost to you.

If you are interested in participating or would like additional information, please call Samantha at 617-643-2076.

 

Recognition and Characterization of Obsessive-Compulsive Symptoms in Postpartum Women:

Participation involves completing a survey that takes no more than 20 minutes:  https://limesurvey.partners.org/limesurvey/index.php/463814?lang=en. For more information, if you have any questions or problems with this study please email the Principal Investigator (Dr. Baer) at baer.lee@mgh.harvard.edu

 

The MGH Center for Women’s Mental Health

Perinatal and Reproductive Psychiatry Program

Simches Research Building

185 Cambridge St Suite 2200

Boston, MA 02114

 

To make an appointment:

Massachusetts General Hospital Clinical Program: (617) 724-7792

Location of appointments: 

Wang Ambulatory Care Center, Massachusetts General Hospital

15 Parkman St., Floor 8

Boston, MA 02114-3117 

Latest News from our Blog

  • Why Are We Still Using Valproic Acid (Depakote) in Women of Childbearing Age?

    May 22, 2017

    Credit: Pregnant Woman from Wikimedia Commons

      There have long been concerns regarding the use of the anticonvulsant valproate (Depakote) during pregnancy.  First trimester use of valproate has been associated with a 3-5% risk of neural tube defects, as well as an increased risk of other malformations affecting the heart, limbs, and genitals. Prenatal exposure to valproate may also result in lower ...

    Read more
  • Ovarian Suppression for PMDD: New Study Suggests Long-Term Effectiveness and Tolerability

    May 17, 2017

      PMDD or premenstrual dysphoric disorder has always been a bit of mystery.  We explain that PMDD is triggered by changes in reproductive hormone levels, but when you look at hormone levels in women with PMDD, they do not differ significantly from the hormone levels of women without PMDD.  Another question is why some women develop ...

    Read more
  • In Brief: High Rates of Marijuana Use in Pregnant Teens

    May 15, 2017

    According to data from the 2002-2015 National Survey on Drug Use and Health, the prevalence of marijuana use was 3.8% in pregnant women (n=14,400), compared to 7.5% in nonpregnant women (n=395,600).   The investigators observed that marijuana use was higher in the first trimester (6.4%) than in the second (3.3%) or third (1.8%) trimesters.  Marijuana use ...

    Read more
  • Brexanolone: Related to Allopregnanolone, Effective for the Treatment of Postpartum Depression

    May 10, 2017

    In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of severe postpartum depression.  SAGE-547, now called brexanolone, is an allosteric modulator of GABAA receptors.  This drug was initially under investigation for the treatment of refractory seizure disorders but it turned out to be a good antidepressant.  The information we ...

    Read more
  • Lamotrigine and Pregnancy: Meta-Analysis Shows No Increase in Risk for Malformations

    May 8, 2017

      Maintenance treatment with a mood stabilizer during pregnancy can significantly reduce the risk of relapse in women with bipolar disorder; however, many of the mood stabilizers commonly used in this setting, including lithium and valproic acid, carry some degree of teratogenic risk. In contrast, lamotrigine (Lamictal) appears to be a much safer option for use ...

    Read more
  • Weekly Roundup for MAY 5, 2017: Recent Publications in Women’s Mental Health

    May 7, 2017

      A slow week.  There is more concerning data regarding the use of marijuana in pregnant women, which is prevalent in pregnant teens.  And an elegant study from Peter Schmidt and David Rubinow which gives us more information regarding the etiology of PMDD and potential strategies for its management.     Marijuana Use During Stages of Pregnancy in ...

    Read more

Read more from our Blog

Recent Awards

banner_postpartum-depression

Awarded by Healthline.com

Awarded by Feedspot.com